


Univ.-Prof. Dr. med. Thomas Wölfel

*28.04.1956

Professor of Hematology and Internal Oncology, C3 Working Group Leader

III. Medical Clinic and Polyclinic University Medical Center of the Johannes Gutenberg University Mainz D-55131 Mainz, Langenbeckstr. 1, building 911



Academia	
1975 - 1982	Studies of human medicine in Würzburg and Mainz
1983	Doctorate (Dr. med.), University of Mainz
1995	Habilitation in Internal Medicine ("Identifizierung von Zielantigenen einer T- lymphozytären Immunantwort gegen Zellen eines menschlichen Melanoms")
Career	
1982 – 1983	Military service as physician
1984 – 1987	Postdoc, Ludwig Institute for Cancer Research, Brussels (Prof. Th. Boon)
since 1987	Working group leader (1987-1996: I. Med. Clinic; since 1996: III. Med. Clinic) at the University Medical Center of the Johannes Gutenberg University Mainz
1987 – 1995	Assistant physician at the I. Medical Clinic (University Medicine Mainz)
1995	Specialist in internal medicine
1995 – 1997	Senior physician at the I. Med. Clinic (gastroenterology)
since 1997	Senior physician at the III. Med. Clinic (hematology/oncology)
1996 – 1999	University lecturer (C2) for internal medicine
1998	Additional title hematology and internal oncology
since 1998	certified member of the European Society for Medical Oncology (ESMO)
since 1999	Professor (C3) for hematology and internal oncology at the University of Mainz
2003-2012	Lecturer at the III. Med. Clinic
04–10/2009	Commissioner director of the III. Med. Clinic
since 2010	Deputy director of the III. Med. Clinic



Awards	
1975 – 1981	Scholarship according to the Bavarian law for the promotion of gifted students
1984 – 1986	Training Scholarship of the German Research Foundation (DFG)
1989	"Vincenz Czerny"-Prize of the German Society for Hematology and Oncology (DGHO)
1995	"Boehringer Ingelheim Prize" of the Medical Faculty of the Johannes Gutenberg University Mainz
2002	Founding member of the Association for Cancer Immunotherapy (CIMT; http://www.cimt.eu/)
2002 – 2008	Chairman of the Scientific Programme Committee of the annual international CIMT Symposia
since 2003	Board member of the CME (continued medical education)-initiative MTTC ("Molecular Targeted Therapy of Cancer") in Germany
2004-2013	Member of the Expert Committee for "Medical and Scientific Promotion of Young Scientists" of the German Cancer Aid
8/2004 – 3/2009	Deputy Speaker of the Research Training Group GRK 1043 "Immunotherapy" of the German Research Foundation (DFG)
since 4/2009	Speaker of the Research Training Group "Immunotherapy" (GRK1043)
since 04/2009	Executive Board Member of the FZI
since 11/2010	Member of the Scientific Advisory Board of CureVac, Tübingen

Selected Publications

Lennerz V*, Gross S*, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U*, Zieschang J, Forssmann U*, **Woelfel T***, Kaempgen E*. <u>Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.</u> *Cancer Immunol Immunother*. 2014 Feb 2. *equal contributions

Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, **Wölfel T**, Hölzel M, Tüting T. <u>Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation</u>. *Nature*. 2012;490(7420):412-6.

Graf C, Heidel S, Tenzer S, Radsak MP, Solem FK, Britten CM, Huber C, Fischer T, **Wölfel T**. A neoepitope generated by a FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. *Blood* 109:2985-2988, 2007

Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, **Wölfel** T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. *Proc Natl Acad Sci USA* 102:246-253, 2005.